GlassScriptPhysician profile
Vincent Ross Smith
NPI 1164771614
$13,473.39
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,781 · 2022: $8,356 · 2023: $3,272 · 2024: $64.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,822 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $835 · Consulting Fee: $520 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,821.55 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $835.00 |
| Consulting Fee | $520.00 |
| Education | $159.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $5,536.53 | 2021-2023 | Ilumya, Winlevi, Absorica Ld |
| Novartis Pharmaceuticals Corporation | $1,572.31 | 2021-2023 | |
| Abbvie INC. | $953.89 | 2021-2024 | |
| Galderma Laboratories, L.P. | $721.80 | 2021-2022 | |
| Leo Pharma INC. | $619.00 | 2022-2023 | Adbry |
| Mayne Pharma Commercial LLC | $494.66 | 2022-2023 | |
| Lilly USA, LLC | $436.21 | 2021-2023 | Taltz, Olumiant |
| Ucb, INC. | $362.21 | 2021-2023 | Cimzia |
| Journey Medical Corporation | $344.50 | 2021-2023 | |
| Genzyme Corporation | $327.38 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $317.66 | 2021-2023 | Dupixent |
| Merz North America, INC. | $302.25 | 2022-2023 | Xeomin |
| Janssen Biotech, INC. | $284.91 | 2021-2023 | Tremfya |
| Dermavant Sciences, INC. | $219.90 | 2022-2023 | Vtama |
| Arcutis Biotherapeutics, INC. | $193.76 | 2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $193.51 | 2021-2023 | Opzelura |
| Amgen INC. | $167.16 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $101.76 | 2021 | |
| Sanofi-Aventis U.S. LLC | $59.99 | 2023 | |
| Sumitomo Pharma America, INC. | $44.36 | 2024 | Gemtesa |
| Pfizer INC. | $34.41 | 2021-2022 | |
| Vyne Pharmaceuticals INC. | $32.20 | 2021 | |
| Genentech USA, INC. | $32.00 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $30.05 | 2022 | |
| Almirall LLC | $24.12 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $24.12 | 2022 | |
| Epi Health, LLC | $21.95 | 2022 | |
| Stemline Therapeutics INC. | $14.67 | 2022 | |
| Biofrontera INC. | $6.12 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.